Department of Clinical Physiology, Nuclear Medicine and PET - Charlotte Lund Denholt, PhD in radiochemistry

In 2001 I got employed as a radiochemist at Copenhagen University Hospital, Rigshospitalet with the production and QC of [18F]FDG and other rutine PET tracers. In 2005 I started my phd-studies. I defended my thesis entitled: “Development of new radiolabelled PET-ligands for a cancer specific epidermal growth factor receptor and their applications for cancer diagnosis” September 17th 2008. The work contained all the steps from synthesis and development of the peptides, the 18F-labelling, and the in vitro and in vivo studies.

During my Ph.D training I worked 6 monthes in Frédéric Dollés group at at Départment de Recherche Médicale, Orsay, France. I worked with fluorine-18 labelling of peptides and the in vivo studies. In my current position at Rigshospitalet I work as QC lab manager, with the responsibility of all the analytical instruments, validation and maintenance. I also work in our research department, developing new radiotracers.

Education:

January 2005- May 2008		Ph.D. in radiochemistry from Faculty of Health Science, Copenhagen University The title of my Ph.D.: Development of new radiolabelled PET-ligands for a cancer specific epidermal growth factor receptor and their applications for cancer diagnosis
August 1998-August 2001		Master of science in chemistry from Faculty of Science, Copenhagen University. The title of my thesis: Model peptides for the characterization of proteases mode of operation. (Studied at Washington State University, Pullman, Washington, USA, August 1998-Maj 1999)
September 1994-June 1997		B.Sc., in chemistry from Faculty of Science, Copenhagen University. Title of my Bachelor project: Determination of Fe in colored food products by flow-injection analysis.
August 1988-June 1991		Graduated from Nørre Gymnasium, with chemistry and mathematics as my mean subjects.

Denholt CL, Binderup T, Stockhausen M, Poulsen HS, Spang-Thomsen M, Hansen PR et al Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nuclear Medicine and Biology. 2011 maj;38(4):509-15.

Denholt CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjaer A. Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library. Biopolymers. 2009;91(3):201-6.

The Curriculum Vitae can be downloaded here as a *PDF file: Charlotte_Lund_Denholt_CV.pdf